Inflammatory Bowel Disease Treatment Market Research Report – Forecast to 2027

Inflammatory Bowel Disease Treatment Market: Information by Drug Class (TNF Inhibitors, Aminosalicylates) Disease Indication (Ulcerative Colitis, Crohn’s Disease) Distribution Channel (Hospital Pharmacy), End-User (Hospitals & Clinics)—Forecast till 2027

ID: MRFR/Pharma/4805-HCR | | Region: Global | 100 pages

Inflammatory Bowel Disease Treatment Market Speak to Analyst Request a Free Sample

Inflammatory Bowel Disease Treatment Market Scenario


The inflammatory bowel disease treatment market is expected to register a CAGR of 2.5% during the forecast period. Inflammatory bowel disease is characterized by chronic inflammation of the digestive tract. It is an umbrella term for ulcerative colitis and Crohn’s disease. The market for inflammatory bowel disease treatment is growing worldwide due to factors such as the increasing prevalence of ulcerative colitis and Crohn’s disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, increasing number of drugs in clinical trial and growing popularity of prebiotic and probiotic foods is likely to spur market growth. However, high capital investments required for drug discovery, unsatisfactory effectiveness of treatment, and stringent drug regulatory policies are restraining the growth of the inflammatory bowel disease treatment market.


Market Segmentation                                                                                                                         


The inflammatory bowel disease treatment market has been segmented on the basis of drug class, disease indication, distribution channel, and end-user. Based on drug class, the market has been segmented into TNF inhibitors, aminosalicylates, immunomodulators, and corticosteroids.


By disease indication, the market has been segmented into ulcerative colitis and Crohn’s disease.


Based on distribution channel, the market has been segmented into hospital pharmacy, retail pharmacy, and online pharmacy.


By end-user, the market has been segmented into hospitals and clinics and others.


Based on region, the market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The market in the Americas has been further segmented into North America and South America. The European market has been further divided into Western Europe and Eastern Europe.


Regional Market Summary


Americas is expected to be the largest inflammatory bowel disease treatment market, by region. The increasing prevalence of anxiety and gluten allergies and inclination towards junk food has led to the increasing number of patients suffering from inflammatory bowel disease in the region. According to the Anxiety and Depression Association of America, anxiety was the most diagnosed mental disorder in the US, with around 40 million people, aged over 14, affected by anxiety every year. As per the Centers for Disease Control and Prevention (CDC), about 1.3% of US adults, approximately 3 million, were diagnosed with IBD, either Crohn’s disease or ulcerative colitis, in 2015. Furthermore, rising health awareness, the presence of key players, and established healthcare infrastructure are likely to enhance the growth of the inflammatory bowel disease treatment market in the region. According to the Centers for Medicare and Medicaid Services (CMS) in 2016, healthcare spending in the US increased by 4.3% to reach USD 3.3 trillion. Thus, increasing per capita income and rising healthcare spending will aid market growth in the Americas.


Europe was the second-largest inflammatory bowel disease treatment market, by region in 2017. The European market is expected to exhibit steady growth during the forecast period owing to the increasing prevalence of inflammatory bowel disease, rising rate of alcohol abuse, unhealthy lifestyle habits, and the increasing incidence of anxiety and depression among adults. Additionally, factors such as increasing government initiatives and funding for research, the development of advanced medical treatment options, and availability of favorable reimbursement policies are likely to propel the growth of the inflammatory bowel disease treatment market in Europe.


Asia-Pacific is expected to be the fastest-growing inflammatory bowel disease treatment market with an exponential rise in patient population. Japan and China are expected to be the largest markets for inflammatory bowel disease treatment in Asia-Pacific. The rising prevalence of anxiety and depression among adults as well as the increasing abuse of alcohol and sedentary lifestyles are expected to result in a growing patient pool, fueling the demand for treatment drugs. Furthermore, comparatively lenient drug regulatory policies and increasing government initiatives for healthcare reform are expected to propel market growth during the forecast period. Rising healthcare expenditure and rising standards of living in the region are also driving the growth of the inflammatory bowel disease treatment market in Asia-Pacific.


The market in the Middle East & Africa is expected to show the least growth due to a lack of awareness about the disease, limited access to and availability of treatment facilities, and lower prevalence of the disorder. However, the market may grow in the UAE, Kuwait, and Saudi Arabia.


Market Players



  • Abbott Laboratories

  • Valeant Pharmaceuticals International

  • Novartis AG

  • Janssen Biotech, Inc.

  • Alkem Laboratories Limited

  • AbbVie, Inc.

  • UCB Inc

  • Takeda Pharmaceutical Company Limited

  • Biogen Inc.

  • Pfizer Inc.

  • Allergan plc


Inflammatory Bowel Disease Treatment Market Share, by Region, 2017 (%)


 Inflammatory Bowel Disease Treatment Market Share


Source: World Health Organization, Centers for Disease Control and Prevention, Expert Interviews, Annual Reports, White Papers, Company Presentations, and Market Research Future Analysis


Market Segmentation and Key players


Inflammatory Bowel Disease Treatment Market, by Drug Class



  • TNF Inhibitors

  • Aminosalicylates

  • Immunomodulators

  • Corticosteroids


Inflammatory Bowel Disease Treatment Market, by Disease Indication



  • Ulcerative Colitis

  • Crohn’s Disease


Inflammatory Bowel Disease Treatment Market, by Distribution Channel



  • Hospital Pharmacy

  • Retail Pharmacy

  • Online Pharmacy


Inflammatory Bowel Disease Treatment Market, by End-User



  • Hospitals and Clinics

  • Others


Inflammatory Bowel Disease Treatment Market, by Region


North America



  • US

  • Canada


South America


Europe



  • Western Europe

  • Germany

  • France

  • UK

  • Italy

  • Spain

  • Rest of Western Europe

  • Eastern Europe


Asia-Pacific



  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Rest of Asia-Pacific


Middle East & Africa



  • UAE

  • Saudi Arabia

  • Oman

  • Kuwait

  • Qatar

  • Rest of the Middle East & Africa


Intended Audience



  • Pharmaceutical manufacturers and suppliers

  • Medical research laboratories

  • Research and development companies

  • Market research and consulting service providers

  • Potential investors



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   2.5% (2018-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Drug Class, Disease Indication, Distribution Channel, and End-user
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Abbott Laboratories, Valeant Pharmaceuticals International, Novartis AG, Janssen Biotech Inc., Alkem Laboratories Limited, AbbVie Inc., UCB Inc, Takeda Pharmaceutical Company Limited, Biogen Inc., Pfizer Inc., Allergan plc
  Key Market Opportunities

  • Increasing number of drugs in clinical trial
  • Growing popularity of prebiotic and probiotic foods
  •   Key Market Drivers

  • Increasing prevalence of ulcerative colitis and Crohn’s disease
  • Advances in medical technology
  • Government support for inflammatory bowel disease treatment research
  • The ubiquity of anxiety and depression


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The forecasted CAGR would be 2.5% during the forecast period for Inflammatory Bowel Disease Treatment Market.

    Demand for high capital investment, lack of effective treatment, strict drug regulations are some of the key factors holding the Inflammatory Bowel Disease Treatment Market back.

    The segments are ulcerative colitis and Crohn’s disease included in Inflammatory Bowel Disease Treatment Market report.

    End users included are hospitals, clinics, and others for the Inflammatory Bowel Disease Treatment Market report.

    The Inflammatory Bowel Disease Treatment Market would be dominated by the Americas.